Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathway

Journal of Neuroscience

Volumn 31, Issue 35, 2011, Pages 12629-12637

  Gantz, Stephanie C ^a   Ford, Christopher P ^b   Neve, Kim A ^c   Williams, John T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; METHYL CPG BINDING PROTEIN 2;

ADULT ANIMAL; AGE DISTRIBUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITE; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ELECTRIC CAPACITANCE; FEMALE; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE FIBER MEMBRANE CONDUCTANCE; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN DEPLETION; RETT SYNDROME; SUBSTANTIA NIGRA; WILD TYPE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; BIOPHYSICS; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; ELECTRIC STIMULATION; ELECTROCHEMICAL TECHNIQUES; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION; MALE; MEMBRANE POTENTIALS; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURAL CONDUCTION; NEURAL PATHWAYS; NEURONS; PATCH-CLAMP TECHNIQUES; PROTEIN BINDING; RADIOLIGAND ASSAY; SEX FACTORS; SUBSTANTIA NIGRA; TRITIUM;

EID: 80052358759     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0684-11.2011     Document Type: Article

References (37)

1. Bath BD, Michael DJ, Trafton BJ, Joseph JD, Runnels PL, Wightman RM (2000) Subsecond adsorption and desorption of dopamine at carbonfiber microelectrodes. Anal Chem 72:5994-6002.
2. Beckstead MJ, Grandy DK, Wickman K, Williams JT (2004) Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron 42:939-946.
3. Beckstead MJ, Gantz SC, Ford CP, Stenzel-Poore MP, Phillips PE, Mark GP, Williams JT (2009) CRF enhancement of GIRK channel-mediated transmission in dopamine neurons. Neuropsychopharmacology 34:1926-1935.
4. Belichenko NP, Belichenko PV, Mobley WC (2009) Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpGbinding protein 2 in the cerebral cortex of female mice with Mecp2 mutation. Neurobiol Dis 34:71-77.
5. Chahrour M, Zoghbi HY (2007) The story of Rett syndrome: from clinic to neurobiology. Neuron 56:422-437.
6. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27:327-331.
7. Colebrooke RE, Humby T, Lynch PJ, McGowan DP, Xia J, Emson PC (2006) Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 24:2622-2630.
8. De Blasi A, Mennini T (1982) Selective reduction of one class of dopamine receptor binding sites in the corpus striatum of aged rats. Brain Res 242:361-364.
9. 2 dopamine receptors in human substantia nigra: localization and the effect of aging. J Neurochem 56:1130-1133.
10. Dunn HG, MacLeod PM (2001) Rett syndrome: review of biological abnormalities. Can J Neurol Sci 28:16-29.
11. FitzGerald PM, Jankovic J, Percy AK (1990) Rett syndrome and associated movement disorders. Mov Disord 5:195-202.
12. Ford CP, Gantz SC, Phillips PE, Williams JT (2010) Control of extracellular dopamine at dendrite and axon terminals. J Neurosci 30:6975-6983.
13. Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27:322-326.
14. Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in mouse model of Rett syndrome. Science 315:1143-1147.
15. Hagberg B (1985) Rett's syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand 74:405-408.
16. Henry JM, Filburn CR, Joseph JA, Roth GS (1986) Effect of aging on striatal dopamine receptor subtypes in Wistar rats. Neurobiol Aging 7:357-361.
17. 2 receptors in corpus striatum of rats. Pharmacol Toxicol 61:126-129.
18. 2-like receptors in human striatum. Synapse 63:282-290.
19. Kishi N, Macklis JD (2010) MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons. Exp Neurol 222:51-58.
20. Koyrakh L, Luján R, Colón J, Karschin C, Kurachi Y, Karschin A, Wickman K (2005) Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J Neurosci 25:11468-11478.
21. Laurvick CL, de Klerk N, Bower C, Christodoulou J, Ravine D, Ellaway C, Williamson S, Leonard H (2006) Rett syndrome in Australia: a review of the epidemiology. J Pediatr 148:347-352.
22. McGill BE, Bundle SF, Yaylaoglu MB, Carson JP, Thaller C, Zoghbi HY (2006) Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 103:18267-18272.
23. Miralvès J, Magdeleine E, Joly E (2007) Design of an improved set of oligonucleotide primers for genotyping MeCP2tm1.1BirdKO mice by PCR. Mol Neurodegener 2:16.
24. 2 receptors. Neuroscience 36:403-410.
25. Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG (2008) Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology 70:1313-1321.
26. 3H] piflutixol. Eur J Pharmacol 105:171-174.
27. Panayotis N, Pratte M, Borges-Correia A, Ghata A, Villard L, Roux JC (2011) Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouse. Neurobiol Dis 41:385-397.
28. Phillips PE, Hancock PJ, Stamford JA (2002) Time window of autoreceptormediated inhibition of limbic and striatal dopamine release. Synapse 44:15-22.
29. Samaco RC, Mandel-Brehm C, Chao HT, Ward CS, Fyffe-Maricich SL, Ren J, Hyland K, Thaller C, Maricich SM, Humphreys P, Greer JJ, Percy A, Glaze DG, Zoghbi HY, Neul JL (2009) Loss of Mecp2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities. Proc Natl Acad Sci U S A 106:21966-21971.
30. Schanen NC (1999) Molecular approaches to the Rett syndrome gene. J Child Neurol 14:806-814.
31. Severson JA, Finch CE (1980) Reduced dopaminergic binding during aging in the rodent striatum. Brain Res 192:147-162.
32. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, Zoghbi H (2002) Mice with truncated Mecp2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35:243-254.
33. Taneja P, Ogier M, Brooks-Harris G, Schmid DA, Katz DM, Nelson SB (2009) Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J Neurosci 29:12187-12195.
34. 3H]raclopride for dopamine D-2 receptor binding to rat striatum. Eur J Pharmacol 173:177-182.
35. Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Peña F, Zanella S, Bévengut M, Barthelemy-Requin M, Herzing LB, Moncla A, Mancini J, Ramirez JM, Villard L, Hilaire G (2005) Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25:11521-11530.
36. Wenk GL, Naidu S, Casanova MF, Kitt CA, Moser H (1991) Altered neurochemical markers in Rett's syndrome. Neurology 41:1753-1756.
37. Williams JT, North RA, Shefner SA, Nishi S, Egan TM (1984) Membrane properties of rat locus coeruleus neurones. Neuroscience 13:137-156.